

1 AN ACT relating to addiction treatment.

2 ***Be it enacted by the General Assembly of the Commonwealth of Kentucky:***

3 ➔Section 1. KRS 304.17A-611 is amended to read as follows:

4 **(1)** A utilization review decision shall not retrospectively deny coverage for health care
5 services provided to a covered person when prior approval has been obtained from
6 the insurer or its designee for those services, unless the approval was based upon
7 fraudulent, materially inaccurate, or misrepresented information submitted by the
8 covered person, authorized person, or the provider.

9 **(2)** ***For health benefit plans issued or renewed on or after the effective date of this***
10 ***section, an insurer shall not require or conduct a prospective or concurrent***
11 ***review for a prescription drug that:***

12 **(a)** ***Is used in the treatment of alcohol or opioid use disorder; and***

13 **(b)** ***Contains Methadone, Buprenorphine, or Naltrexone.***

14 ➔Section 2. KRS 205.536 is amended to read as follows:

15 (1) A Medicaid managed care organization shall have a utilization review plan, as
16 defined in KRS 304.17A-600, that meets the requirements established in 42 C.F.R.
17 pts. 431, 438, and 456. If the Medicaid managed care organization utilizes a private
18 review agent, as defined in KRS 304.17A-600, the agent shall comply with all
19 applicable requirements of KRS 304.17A-600 to 304.17A-633.

20 (2) In conducting utilization reviews for Medicaid benefits, each Medicaid managed
21 care organization shall use the medical necessity criteria selected by the Department
22 of Insurance pursuant to KRS 304.38-240, for making determinations of medical
23 necessity and clinical appropriateness pursuant to the utilization review plan
24 required by subsection (1) of this section.

25 **(3)** ***The Department for Medicaid Services or any managed care organization***
26 ***contracted to provide Medicaid benefits pursuant to KRS Chapter 205 shall not***
27 ***require or conduct a prospective or concurrent review, as defined in KRS***

1 304.17A-600, for a prescription drug that:

2 (a) Is used in the treatment of alcohol or opioid use disorder; and

3 (b) Contains Methadone, Buprenorphine, or Naltrexone.

4 ➔SECTION 3. A NEW SECTION OF SUBTITLE 17A OF KRS CHAPTER 304
5 IS CREATED TO READ AS FOLLOWS:

6 (1) As used in this section, "State Board of Medical Licensure" means the board
7 established in KRS 311.530.

8 (2) For all claims made during the preceding plan year, an insurer shall annually
9 report to the commissioner the number and type of providers that have prescribed
10 medication for addiction treatment to its insureds:

11 (a) In conjunction with behavioral therapy; and

12 (b) Not in conjunction with behavioral therapy.

13 (3) The commissioner shall submit an annual written report, which shall include an
14 executive summary, to the General Assembly and the State Board of Medical
15 Licensure on the information reported under subsection (2) of this section.

16 ➔Section 4. KRS 205.522 is amended to read as follows:

17 (1) The Department for Medicaid Services and any managed care organization
18 contracted to provide Medicaid benefits pursuant to this chapter shall comply with
19 the provisions of KRS 304.17A-167, 304.17A-235, 304.17A-515, 304.17A-580,
20 304.17A-600, 304.17A-603, 304.17A-607, and 304.17A-740 to 304.17A-743, as
21 applicable.

22 (2) A managed care organization contracted to provide Medicaid benefits pursuant to
23 this chapter shall comply with the reporting requirements of Section 3 of this Act.

24 ➔Section 5. Section 1 takes effect January 1, 2022.